Posted by Michael Wonder on 27 Jun 2022
Lynparza recommended for approval in the EU by CHMP as adjuvant treatment for patients with germline BRCA mutated HER2 negative high risk early breast cancer
27 June 2022 - First PARP inhibitor to improve overall survival in early-stage breast cancer.
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2 negative high risk early breast cancer previously treated with neo-adjuvant or adjuvant chemotherapy.
